Co-inhibition by CTLA4

Summary
Organism
Homo sapiens (human)
Reactome
R-HSA-389513
PubChem
R-HSA-389513
Description
  • Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an immune checkpoint molecule predominantly expressed on the surface of activated T cells and regulatory T (Treg) cells. It plays a critical role in inhibiting T-cell activation and maintaining immune homeostasis (Alegre et al. 2001). After acctivation of T lymphocytes through their antigen receptor (TCR) induces the upregulation of CTLA-4 expression. CTLA-4 engagement alongside TCR activation inhibits T cell responses through two primary mechanisms: competing with CD28 for B7 binding to reduce costimulation, and delivering a negative signal directly into the T cells. It has been reported that phosphotyrosine-dependent recruitment of the SHP-2 phosphatase to CTLA-4 inhibits T cell activation and expansion by dephosphorylation of CD3/TCR chains.
    CTLA-4 inhibits T cell activation through several mechanisms, including the reduction of IL-2 production and expression, as well as by arresting T cells in the G1 phase of the cell cycle (Greenwald et al. 2002). This checkpoint molecule not only impacts the T cells that express it but also exerts a dominant regulatory influence on the proliferation of other T cells. This ability to limit the proliferation of surrounding T cells is crucial in preventing autoreactivity and maintaining immune tolerance, ensuring that the immune system does not inadvertently target the body's own tissues.
    Due to its ability to modulate immune responses, CTLA-4 has emerged as a significant therapeutic target for managing conditions such as cancer, autoimmune diseases, and transplant rejection (Tivol et al. 1995, Chambers et al. 1997, Rudd and Schneider 2003).
Click on a node on the pathway to see its details. Glycoproteins are marked with a glycoprotein icon in their name.

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: [email protected]

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.5.0

Last updated: April 6, 2026